| Jour | Date | Titre | Effet sur
le cours | CAC40 |
|---|
| 27/03/2024 | 21:01 (J-1) | Appoints andrew dickinson as non-executive non-independent director to its board | -0.07% | +0.25% |
| 23/02/2024 | 21:01 (J-1) | Announces full year 2023 results and outlook for 2024 | -7.72% | +0.7% |
| 01/02/2024 | 21:01 (J-1) | Completes transaction to transfer jyseleca® business to alfasigma | -1.23% | -0.89% |
| 05/01/2024 | 21:01 (J-1) | Enters into strategic collaboration agreement with thermo fisher scientific to further expand its decentralized car-t manufacturing netw... | -0.58% | -0.4% |
| 04/01/2024 | 21:01 (J-1) | Establishes strategic collaboration with bridgene biosciences to expand small molecule drug discovery in oncology | -0.05% | +0.52% |
| 02/01/2024 | 06:00 | Signs agreement to transfer jyseleca® business to alfasigma | +1.51% | -0.16% |
| 20/12/2023 | 21:01 (J-1) | Announces start of papilio-1 phase 1/2 multiple myeloma study of point-of-care manufactured bcma car-t candidate, glpg5301 | +0.81% | +0.12% |
| 08/12/2023 | 21:01 (J-1) | To host kol event on december 10, 2023, at 11:00 am pst to discuss new data presented at ash 2023 | -0.57% | +1.32% |
| 31/10/2023 | 21:01 (J-1) | Concludes strategic evaluation and signs letter of intent to transfer jyseleca® business to alfasigma | 0.71% | +0.89% |
| 29/08/2023 | 14:46 | Début d'un essai de phase ii dans le lupus | 0% | +0.67% |
| 21:01 (J-1) | Announces start of phase 2 study with selective tyk2 inhibitor, glpg3667, in patients with active systemic lupus erythematosus |
| 13/06/2023 | 10:38 | Nomme le dr. susanne schaffert en tant qu'administrateur indépendant non exécutif | -1.34% | +0.56% |
| 21:01 (J-1) | Appoints dr. susanne schaffert as non-executive independent director to its board |
| 06/06/2023 | 21:01 (J-1) | To showcase car-t point-of-care manufacturing and initial phase 1/2 cll data with cd19 car-t candidate, glpg5201, at the eha 2023 congress | +1.52% | +0.11% |
| 24/05/2023 | 21:01 (J-1) | Announces start of phase 2 study with selective tyk2 inhibitor, glpg3667, in patients with dermatomyositis | -1.83% | -1.7% |
| 08/05/2023 | 21:01 (J-3) | Creates new subscription right plans | -2.36% | +0.11% |
| 24/03/2023 | 21:01 (J-1) | Publishes 2022 annual report and announces annual shareholders' meeting | +-0.29% | -1.74% |
| 24/02/2023 | 21:01 (J-1) | Announces full year 2022 results and outlook for 2023 | -2.74% | -1.78% |
| 11/01/2023 | 21:01 (J-1) | Receives transparency notification from fmr llc | -0.14% | +0.8% |
| 04/01/2023 | 21:01 (J-1) | To present at 41th annual j.p. morgan healthcare conference | -2.01% | +2.3% |
| 27/12/2022 | 21:01 (J-4) | Receives transparency notification from fmr llc | 0% | +0.7% |
| 13/12/2022 | 06:00 | And cellpoint presented encouraging initial data at ash 2022 for glpg5101, a cd19 car-t candidate manufactured at point-of-care | 0.25% | +1.42% |
| 07/11/2022 | 21:01 (J-3) | Presents roadmap for pipeline and commercial growth at its r&d day 2022 | -4.14% | +0% |
| 13/10/2022 | 17:01 | Morgan stanley maintient son opinion neutre | 0.64% | +1.04% |
| 07/10/2022 | 21:01 (J-1) | Provides further insights into the treatment of ulcerative colitis at the upcoming united european gastroenterology (ueg) week 2022 cong... | +-0.67% | -1.17% |
| 05/10/2022 | 19:30 (J-1) | Dit avoir décroché un avis réglementaire positif sur la mise à jour de l'étiquette européenne de jyseleca -- les actions sont en h... | -1% | -0.9% |
| 04/10/2022 | 05:12 | Obtient le soutien de l'agence européenne de santé pour supprimer l'avertissement relatif à la fertilité masculine sur l'étiquette ... | 2.41% | +4.24% |
| 09/09/2022 | 15:00 | Morgan stanley n'est plus à l'achat | -2.17% | +1.41% |
| 30/08/2022 | 21:01 (J-1) | Receives transparency notification from fmr llc | +1.97% | -0.19% |
| 19/08/2022 | 21:01 (J-1) | Receives transparency notification from fmr llc | +0.42% | -0.94% |
| 15/08/2022 | 16:00 | Morgan stanley toujours à l'achat | +1.2% | +0.25% |
| 09/08/2022 | 21:01 (J-1) | Receives transparency notification from fmr llc | -0.79% | -0.53% |
| 08/08/2022 | 15:00 | Rbc capital markets neutre sur le dossier | 0.38% | +0.8% |
| 17:53 (J-3) | Réduit sa perte au 2e trimestre et réduit son revenu net |
| 05/08/2022 | 21:01 (J-1) | First key steps in pipeline rebuild and strong commercial progress in h1 2022 | +3.02% | -0.63% |
| 18/07/2022 | 20:01 (J-3) | Morgan stanley persiste à l'achat | +1.13% | +0.93% |
| 22/06/2022 | 06:18 | Le groupe pharmaceutique galapagos achète les développeurs de thérapies cellulaires cellpoint et aboundbio pour 251 millions $. | -3.31% | -0.81% |
| 21:03 (J-1) | To acquire cellpoint and aboundbio to accelerate access to next-generation cell therapies |
| 21/06/2022 | 21:01 (J-1) | Increases share capital through subscription right exercises | 0.49% | +0.75% |
| 02/06/2022 | 21:01 (J-1) | Receives transparency notification from fmr llc | 0.39% | +1.27% |
| 26/05/2022 | 21:01 (J-1) | To showcase commitment to rheumatoid arthritis care at the upcoming european league against rheumatism congress | +2.06% | +1.78% |
| 25/05/2022 | 15:22 | Acquiert sous licence de scipher des cibles médicamenteuses pour les maladies inflammatoires de l'intestin | 0.19% | +0.73% |
| 09/05/2022 | 14:01 | Rbc capital markets toujours neutre sur le dossier | -3.33% | -2.75% |
| 21:01 (J-3) | Creates new subscription right plans |
| 06/05/2022 | 21:01 (J-1) | Demonstrates regulatory and commercial progress in q1 2022 | +0.28% | -1.73% |
| 02/05/2022 | 12:22 | Le titre revient à proximité du support | +0.89% | -1.66% |
| 13/04/2022 | 07:59 | E-therapeutics plc annonce une étape clé dans sa collaboration avec galapagos | -2.63% | +0.07% |
| 28/03/2022 | 14:23 | Nouvelle approbation pour jyseleca au japon | +1.01% | +0.54% |
| 08:42 | Jyseleca des galápagos reçoit le feu vert du japon pour le traitement de la colite ulcéreuse |
| 07:01 | Jyseleca® approved in japan for ulcerative colitis |
| 25/03/2022 | 21:16 (J-1) | Correction: galapagos publishes 2021 annual report and announces extraordinary and annual shareholders' meetings | -0.79% | -0.03% |
| 21/03/2022 | 22:01 (J-3) | Increases share capital through subscription right exercises | -2.41% | -0.57% |
| 25/02/2022 | 21:01 (J-1) | 2021 results set stage for future growth | +3.55% | +3.55% |
| 04/02/2022 | 21:01 (J-1) | Receives transparency notification from ecor1 capital | +1.58% | -0.77% |
| 03/02/2022 | 21:01 (J-1) | Provides further insights into the treatment of ulcerative colitis at the european crohn's and colitis organization (ecco) annual congress | -3.93% | -1.54% |
| 28/01/2022 | 16:00 | Bryan, garnier & co. n'est plus à la vente | +1.93% | -0.82% |
| 19:23 (J-1) | Les actions du secteur de la santé continuent de surperformer dans un contexte de baisse des marchés jeudi. |
| 18:38 (J-1) | Nomme paul stoffels, ancien cadre de johnson & johnson, au poste de pdg les actions s'envolent. |
| 27/01/2022 | 04:30 | Nomme un ancien cadre de johnson & johnson pour succéder au pdg qui prend sa retraite | +22.58% | +0.6% |
| 21:01 (J-1) | Appoints paul stoffels as chief executive officer |
| 19/01/2022 | 04:16 | Obtient l'aval du royaume-uni pour le médicament jyseleca contre les maladies inflammatoires de l'intestin. | -1.45% | +0.55% |
| 21:01 (J-1) | Jyseleca®? (filgotinib) licensed for the treatment of adult patients with moderately to severely active ulcerative colitis in great bri... |
| 17/01/2022 | 20:01 (J-3) | Le conseil de surveillance de galapagos crée un plan de 30 000 droits de souscription | +3.29% | +0.82% |
| 14/01/2022 | 21:01 (J-1) | Creates new subscription right plan | +3% | -0.81% |
| 06/01/2022 | 14:30 | To present at 40th annual j.p. morgan healthcare conference | +-1.1% | -1.72% |
| 06/12/2021 | 21:01 (J-3) | Increases share capital through subscription right exercises | +4.01% | +1.48% |
| 23/11/2021 | 05:03 | Achève le recrutement de patients dans le cadre d'une étude sur les maladies rénales de stade intermédiaire. | -4.17% | -0.85% |
| 21:01 (J-1) | Completes patient recruitment for mangrove phase 2 trial with glpg2737 in polycystic kidney disease |
| 18/11/2021 | 00:00 | Jefferies london healthcare conference | +0.27% | -0.21% |
| 16/11/2021 | 17:46 (J-1) | Obtient de la commission européenne l'autorisation de mise sur le marché d'un traitement contre la colite ulcéreuse | -0.77% | +0.34% |
| 05/11/2021 | 22:01 (J-1) | Reports commercial and operational progress at q3 financial results | -2.39% | +0.76% |
| 05/10/2021 | 21:01 (J-1) | Presents new data from the selection phase 3 program at the united european gastroenterology week (uegw) 2021 congress | -1.01% | +1.52% |
| 04/10/2021 | 07:57 | Achève le recrutement de patients dans le cadre d'une étude sur les maladies inflammatoires de l'intestin en phase avancée. | -4.35% | -0.61% |
| 22/09/2021 | 00:00 | Bernstein strategic decisions virtual conference | -0.18% | +1.29% |
| 21/09/2021 | 06:13 | émet de nouvelles actions pour l'exercice des droits de souscription | -1.88% | +1.5% |
| 17/09/2021 | 14:50 | Obtient un avis réglementaire positif de l'agence européenne des médicaments sur un candidat médicament contre la colite ulcéreuse | +0.69% | -0.79% |
| 19/08/2021 | 13:00 | Barclays dégrade son opinion à neutre | -4.98% | -2.43% |
| 06/08/2021 | 21:01 (J-1) | Reports h1 financial results with refocused pipeline and operational progress | +0.77% | +0.53% |
| 15/07/2021 | 11:28 | Des résultats cliniques décevants | -13.7% | -0.99% |
| 07:07 | Données de phase ib positives en psoriasis |
| 21:01 (J-1) | Demonstrates early clinical activity with sik2/3 inhibition in inflammation |
| 21:01 (J-1) | Reports positive topline results with selective tyk2 inhibitor glpg3667 in phase 1b psoriasis study |
| 23/06/2021 | 21:01 (J-1) | Announces departure of cso piet wigerinck later this year | -3.84% | -0.91% |
| 08/06/2021 | 21:01 (J-1) | Increases share capital through subscription right exercises | +1.12% | +0.11% |
| 04/06/2021 | 06:01 | Selection study on filgotinib in ulcerative colitis published in the lancet | +0.89% | +0.12% |
| 19/05/2021 | 21:01 (J-1) | Announces first patient enrolled in filosophy study to advance understanding of jyseleca (filgotinib) effectiveness and safety in a real... | -3.67% | -1.43% |
| 10/05/2021 | 13:43 | Les ambitions de croissance externe n'enthousiasment pas le marché | -6.24% | +0.01% |
| 07/05/2021 | 21:01 (J-1) | Refocuses pipeline and rightsizes operations | +0.89% | +0.45% |
| 05/05/2021 | 21:01 (J-1) | Transparency notification received from the capital group | -0.33% | +1.4% |
| 03/05/2021 | 21:01 (J-3) | Creates new subscription right plans | -0.57% | +0.61% |
